Drug Profile
GB 001
Alternative Names: ADC3680; ADC3680B; GB001; PTR-36Latest Information Update: 29 Dec 2022
Price :
$50
*
At a glance
- Originator Pulmagen Therapeutics
- Developer Gossamer Bio; Pulmagen Therapeutics; Teijin
- Class Anti-inflammatories; Antiasthmatics; Small molecules
- Mechanism of Action Prostaglandin D2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Allergic asthma; Asthma
- Discontinued Rhinosinusitis
Most Recent Events
- 29 Dec 2022 Phase II development in Asthma (In adults, In the elderly) is still ongoing in France, Austria, Poland, Ukraine, United Kingdom, Canada (PO)
- 31 Mar 2021 GB 001 is available for licensing as of 31 Mar 2020. https://www.gossamerbio.com/
- 13 Oct 2020 Discontinued - Phase-II for Rhinosinusitis (Combination therapy) in Ukraine, Czech Republic, USA (PO)